Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02746809 · ClinicalTrials.gov registry record · NA
Medtronic CoreValve Evolut R U.S. Clinical Study (Evolut 34R Addendum)
A NA study, sponsored by Medtronic Cardiovascular.
- Completed
- Registry status
- NA
- Development phase
- 72
- Enrollment target
NCT02746809 is a NA study that has completed, run by Medtronic Cardiovascular. The registered enrollment target is 72 participants.
The verdict
NCT02746809, a NA study, has completed, sponsored by Medtronic Cardiovascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
Study Summary
The study objectives are to assess the safety and efficacy of the CoreValve Evolut 34R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis who are considered at high or extreme risk for surgical aortic valve replacement.
Interventions
- DEVICE CoreValve Evolut 34R TAVR system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-06 |
| Est. Completion | 2021-12-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02746809
The ClinicalTrials.gov registry entry for NCT02746809 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CoreValve Evolut 34R TAVR system is the first listed.
NCT02746809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02746809 about?
NCT02746809 is a clinical study titled "Medtronic CoreValve Evolut R U.S. Clinical Study (Evolut 34R Addendum)". The study objectives are to assess the safety and efficacy of the CoreValve Evolut 34R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis who are considered at high or extreme risk for surgical aortic valve replacement.
What is the current status of trial NCT02746809?
This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2016-06. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT02746809?
The interventions under investigation include: CoreValve Evolut 34R TAVR system (DEVICE).
Who is sponsoring clinical trial NCT02746809?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.